|
4 Low-Priced Biotech Stocks Poised To Rally In 2012
Seeking Alpha In the product development pipeline, Xenoport has candidates for restless legs syndrome and Parkinson's, which recently received negative results in clinical trials. That news caused a big drop in the share price. On the positive side, the FDA approved … |
View full post on restless leg syndrome – Google News
